Fatemeh Hasani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatemeh Hasani has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Kimia Jazi
Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
4 shared publications - Alireza Norouzi
Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
3 shared publications Kimia Jazi
School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
3 shared publicationsSina Khamaki
Golestan Research Center of Gastroenterology and Hepatology Golestan University of Medical Sciences Gorgan Iran
3 shared publicationsZahra Norouzi
Golestan Research Center of Gastroenterology and Hepatology Golestan University of Medical Sciences Gorgan Iran
3 shared publicationsAntonio L. Teixeira
Biggs Institute The University of Texas Health Science Center at San Antonio San Antonio Texas USA
2 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (1) , e70974
Peripheral Blood Leukocyte Ratios as Novel Biomarkers in Brain Glioma: A Comprehensive Systematic Review and Meta‐Analysis
Inflammatory biomarkers, such as leukocyte ratios, have emerged as promising tools for diagnosing and prognosticating brain gliomas. This study systematically reviewed and analysed the diagnostic and prognostic relevance of peripheral blood leukocyte ratios in glioma. Following the PRISMA guidelines, we conducted a systematic review and meta‐analysis by searching PubMed, Web of Science, and Scopus for studies published in English. Eligible studies evaluated the sensitivity, specificity, and area under the curve (AUC) of inflammatory ratios, as well as their associations with survival outcomes. Quality was assessed using the Newcastle‐Ottawa Scale. A total of 29 assessments with 13,189 observations compared the neutrophil‐to‐lymphocyte ratio (NLR) between glioma patients and non‐glioma groups, yielding a pooled standardised mean difference (SMD) of 0.445 (95% CI: 0.280–0.609, p < 0.0001; I 2 = 85.1%). When compared to healthy individuals (10 assessments, 4444 observations), glioma patients exhibited a significantly elevated NLR (SMD: 0.797, 95% CI: 0.576–1.019, p < 0.0001; I 2 = 87.5%). Compared to meningioma (5 assessments, 3227 observations), glioma patients had a significantly higher NLR (SMD: 0.352, 95% CI: 0.280–0.424, p < 0.0001; I 2 = 24.7%). In comparisons with brain metastasis (4 assessments, 428 observations), the difference was not significant (SMD: −0.112, p = 0.3315; I 2 = 44.6%). The platelet‐to‐lymphocyte ratio (PLR) (25 assessments, 12,085 observations) showed no significant difference between glioma and non‐glioma groups (SMD: 0.1291, p = 0.0836; I 2 = 81.4%). Similarly, the derived NLR (dNLR) was significantly higher in glioma patients than in non‐glioma groups (SMD: 0.2421, p < 0.0001; I 2 = 49.9%). The lymphocyte‐to‐monocyte ratio (LMR) was significantly lower in glioma compared to meningioma (SMD: −0.2989, p < 0.0001; I 2 = 0.0%). MLR analysis showed high heterogeneity ( I 2 = 99.5%) with non‐significant findings ( p = 0.4476). These findings suggest NLR and dNLR as potential biomarkers for glioma diagnosis. Peripheral blood leukocyte ratios, particularly NLR, represent valuable biomarkers for glioma diagnosis and prognosis. Further research is warranted to enhance their precision and clinical utility.
- 8 January 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (1) , e70974
Open AccessPeripheral Blood Leukocyte Ratios as Novel Biomarkers in Brain Glioma: A Comprehensive Systematic Review and Meta‐Analysis
Inflammatory biomarkers, such as leukocyte ratios, have emerged as promising tools for diagnosing and prognosticating brain gliomas. This study systematically reviewed and analysed the diagnostic and prognostic relevance of peripheral blood leukocyte ratios in glioma. Following the PRISMA guidelines, we conducted a systematic review and meta‐analysis by searching PubMed, Web of Science, and Scopus for studies published in English. Eligible studies evaluated the sensitivity, specificity, and area under the curve (AUC) of inflammatory ratios, as well as their associations with survival outcomes. Quality was assessed using the Newcastle‐Ottawa Scale. A total of 29 assessments with 13,189 observations compared the neutrophil‐to‐lymphocyte ratio (NLR) between glioma patients and non‐glioma groups, yielding a pooled standardised mean difference (SMD) of 0.445 (95% CI: 0.280–0.609, p < 0.0001; I 2 = 85.1%). When compared to healthy individuals (10 assessments, 4444 observations), glioma patients exhibited a significantly elevated NLR (SMD: 0.797, 95% CI: 0.576–1.019, p < 0.0001; I 2 = 87.5%). Compared to meningioma (5 assessments, 3227 observations), glioma patients had a significantly higher NLR (SMD: 0.352, 95% CI: 0.280–0.424, p < 0.0001; I 2 = 24.7%). In comparisons with brain metastasis (4 assessments, 428 observations), the difference was not significant (SMD: −0.112, p = 0.3315; I 2 = 44.6%). The platelet‐to‐lymphocyte ratio (PLR) (25 assessments, 12,085 observations) showed no significant difference between glioma and non‐glioma groups (SMD: 0.1291, p = 0.0836; I 2 = 81.4%). Similarly, the derived NLR (dNLR) was significantly higher in glioma patients than in non‐glioma groups (SMD: 0.2421, p < 0.0001; I 2 = 49.9%). The lymphocyte‐to‐monocyte ratio (LMR) was significantly lower in glioma compared to meningioma (SMD: −0.2989, p < 0.0001; I 2 = 0.0%). MLR analysis showed high heterogeneity ( I 2 = 99.5%) with non‐significant findings ( p = 0.4476). These findings suggest NLR and dNLR as potential biomarkers for glioma diagnosis. Peripheral blood leukocyte ratios, particularly NLR, represent valuable biomarkers for glioma diagnosis and prognosis. Further research is warranted to enhance their precision and clinical utility.
- Open Access
- 2 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (18) , e42316
Medical education research quality (MERSQ) checklist development: Are searches of BEME and non-BEME reviews standard?: A mixed method study
Even though there has been a lot of research in medical education, the quality of it has not increased similarly. This study aimed to provide a valid and reliable user-friendly tool for evaluating search strategies in medical education systematic reviews. This mixed study was conducted in 2019 to 2021, including 3 phases: systematic search, developing a medical education research quality (MERSQ) checklist, and evaluation of the search quality of best evidence in medical education collaboration (BEME) and non-BEME reviews. Three hundred nineteen items were retrieved from the systematic search of PubMed, Embase, Scopus, Psychinfo, ERIC, and Google Scholar. Following ensuring acceptable criteria, 30 items were included in comprehensiveness or reproducibility guarantees. The results showed that the instrument had an the intra-class correlation coefficient of 0.922 (P = .002), the reproducibility guarantee had 0.903 (P = .003), and the comprehensiveness guarantee had 0.926 (P = .006). We also calculated inter-rater reliability and internal consistency using Cronbach alpha of 0.827 (P < .001) and an instrument the intra-class correlation coefficient of 0.978. Using MERSQ, the overall search quality (41.75 vs 31.25, P = .009), reproducibility (22 vs 14.50, P = .004), and comprehensive score (18.75 vs 15.75, P = .880) of BEME studies were higher than non-BEME ones. Moreover, we found only 30% of studies completed searching documents. The search strategy query concerning the selection of synonym terms received the lowest score among studies. This study led to the development of a valid and reliable checklist for evaluating the search quality of medical education systematic reviews. Utilizing the MERSQ checklist, we found that BEME studies had higher quality than non-BEME ones, making the results from BEME studies more reliable.
- 2 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (18) , e42316
Open AccessMedical education research quality (MERSQ) checklist development: Are searches of BEME and non-BEME reviews standard?: A mixed method study
Even though there has been a lot of research in medical education, the quality of it has not increased similarly. This study aimed to provide a valid and reliable user-friendly tool for evaluating search strategies in medical education systematic reviews. This mixed study was conducted in 2019 to 2021, including 3 phases: systematic search, developing a medical education research quality (MERSQ) checklist, and evaluation of the search quality of best evidence in medical education collaboration (BEME) and non-BEME reviews. Three hundred nineteen items were retrieved from the systematic search of PubMed, Embase, Scopus, Psychinfo, ERIC, and Google Scholar. Following ensuring acceptable criteria, 30 items were included in comprehensiveness or reproducibility guarantees. The results showed that the instrument had an the intra-class correlation coefficient of 0.922 (P = .002), the reproducibility guarantee had 0.903 (P = .003), and the comprehensiveness guarantee had 0.926 (P = .006). We also calculated inter-rater reliability and internal consistency using Cronbach alpha of 0.827 (P < .001) and an instrument the intra-class correlation coefficient of 0.978. Using MERSQ, the overall search quality (41.75 vs 31.25, P = .009), reproducibility (22 vs 14.50, P = .004), and comprehensive score (18.75 vs 15.75, P = .880) of BEME studies were higher than non-BEME ones. Moreover, we found only 30% of studies completed searching documents. The search strategy query concerning the selection of synonym terms received the lowest score among studies. This study led to the development of a valid and reliable checklist for evaluating the search quality of medical education systematic reviews. Utilizing the MERSQ checklist, we found that BEME studies had higher quality than non-BEME ones, making the results from BEME studies more reliable.
- 14 February 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (2) , 190-196
Correlation Between Different Shapes of Major Papilla With Outcomes of Endoscopic Retrograde Cholangiopancreatography in a Prospective Study
Introduction: Several factors affect the difficulty, clinical success, and side effects related to endoscopic retrograde cholangiopancreatography (ERCP), of which the endoscopic appearance of the major papilla is one of the most important. This study aimed to investigate the outcomes related to ERCP in relation to major papilla morphology. Methods: This study was performed prospectively on 581 patients undergoing ERCP. During ERCP, the endoscopist determined the morphology of the major papilla before the cannulation. Primary outcomes included overall operative success rate and post-ERCP pancreatitis (PEP) at 30 days. Secondary outcomes included clinically significant bleeding, perforation, cholangitis or sepsis, difficult cannulation, number of cannulation attempts, and duration of cannulation. Results: Papilla type 2 (OR=2.36, 95% CI: 1.07-5.20) and type 3b (OR=3.19, 95% CI: 1.16-8.73) were associated with decreased odds of procedure success. PEP was directly associated with type 4 papilla (OR=3.30, 95% CI: 1.21-8.98). There were direct correlation between difficult cannulation and types 3a (OR=1.89, 95% CI: 1.20-2.98) and 3b (OR=5.05, 95% CI: 1.98-12.86), cannulation duration more than 10 minutes and types 2 (OR=2.66, 95% CI: 1.31-5.39), 3a (OR=2.18, 95% CI:1.30-3.64), and 3b (OR=4.97, 95% CI: 1.94-12.71), and attempted cannulation more than 5 times and types 3a (OR=1.64, 95% CI: 1.01-2.69), and 3b (OR=4.40, 95% CI: 1.75-11.09). Conclusion: The findings of this study showed that ERCP failure is associated with types 2 and 3b papilla, and papilla type 4 is an independent risk factor for PEP.
- 14 February 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (2) , 190-196
Correlation Between Different Shapes of Major Papilla With Outcomes of Endoscopic Retrograde Cholangiopancreatography in a Prospective Study
Introduction: Several factors affect the difficulty, clinical success, and side effects related to endoscopic retrograde cholangiopancreatography (ERCP), of which the endoscopic appearance of the major papilla is one of the most important. This study aimed to investigate the outcomes related to ERCP in relation to major papilla morphology. Methods: This study was performed prospectively on 581 patients undergoing ERCP. During ERCP, the endoscopist determined the morphology of the major papilla before the cannulation. Primary outcomes included overall operative success rate and post-ERCP pancreatitis (PEP) at 30 days. Secondary outcomes included clinically significant bleeding, perforation, cholangitis or sepsis, difficult cannulation, number of cannulation attempts, and duration of cannulation. Results: Papilla type 2 (OR=2.36, 95% CI: 1.07-5.20) and type 3b (OR=3.19, 95% CI: 1.16-8.73) were associated with decreased odds of procedure success. PEP was directly associated with type 4 papilla (OR=3.30, 95% CI: 1.21-8.98). There were direct correlation between difficult cannulation and types 3a (OR=1.89, 95% CI: 1.20-2.98) and 3b (OR=5.05, 95% CI: 1.98-12.86), cannulation duration more than 10 minutes and types 2 (OR=2.66, 95% CI: 1.31-5.39), 3a (OR=2.18, 95% CI:1.30-3.64), and 3b (OR=4.97, 95% CI: 1.94-12.71), and attempted cannulation more than 5 times and types 3a (OR=1.64, 95% CI: 1.01-2.69), and 3b (OR=4.40, 95% CI: 1.75-11.09). Conclusion: The findings of this study showed that ERCP failure is associated with types 2 and 3b papilla, and papilla type 4 is an independent risk factor for PEP.
- Open Access
- 24 January 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (2) , e70337
Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta‐Analysis
Pancreatic cancer (PC) remains a significant contributor to global cancer mortality, with limited effective diagnostic and prognostic tools. MicroRNAs (miRNAs) have emerged as promising biomarkers for PC diagnosis and prognosis. A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus. Studies reporting sensitivity, specificity or area under the curve (AUC) for miRNAs in PC diagnosis, as well as hazard ratios (HRs) for survival evaluations, were included. Data extraction and quality assessment followed PRISMA guidelines. Meta‐analyses were conducted using appropriate statistical methods. The protocol is registered in PROSPERO. Diagnostic analysis included 290 evaluations, revealing an overall AUC of 0.8226 for PC diagnosis. Subgroup analyses showed varying accuracies, with blood and tissue specimens yielding higher AUC values. Promising miRNAs with AUC values above 0.8 included miR‐320, miR‐1290, miR‐93, miR‐25, miR‐451, miR‐20, miR‐21, miR‐223 and miR‐122. Prognostic analysis encompassed 46 studies, indicating significant associations between miRNA expression and overall survival (OS) and progression‐free survival (PFS). The combined HR for studies reporting OS HRs higher than one was 1.7613 (95% CI: 1.5394–2.0152, p < 0.0001; I2 = 81.7%). Notable miRNAs with prognostic significance included miR‐10, miR‐21 and miR‐221. Studies reporting OS HRs less than one had a pooled HR of 0.6805 (95% CI: 0.5862–0.7901, p < 0.0001; I2 = 65.4%). MiRNAs hold promise as diagnostic and prognostic biomarkers for PC. Blood and tissue specimens offer superior diagnostic accuracy, and several miRNAs show potential for predicting patient outcomes.
- 24 January 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (2) , e70337
Open AccessDiagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta‐Analysis
Pancreatic cancer (PC) remains a significant contributor to global cancer mortality, with limited effective diagnostic and prognostic tools. MicroRNAs (miRNAs) have emerged as promising biomarkers for PC diagnosis and prognosis. A comprehensive literature search was conducted in PubMed, Web of Science, and Scopus. Studies reporting sensitivity, specificity or area under the curve (AUC) for miRNAs in PC diagnosis, as well as hazard ratios (HRs) for survival evaluations, were included. Data extraction and quality assessment followed PRISMA guidelines. Meta‐analyses were conducted using appropriate statistical methods. The protocol is registered in PROSPERO. Diagnostic analysis included 290 evaluations, revealing an overall AUC of 0.8226 for PC diagnosis. Subgroup analyses showed varying accuracies, with blood and tissue specimens yielding higher AUC values. Promising miRNAs with AUC values above 0.8 included miR‐320, miR‐1290, miR‐93, miR‐25, miR‐451, miR‐20, miR‐21, miR‐223 and miR‐122. Prognostic analysis encompassed 46 studies, indicating significant associations between miRNA expression and overall survival (OS) and progression‐free survival (PFS). The combined HR for studies reporting OS HRs higher than one was 1.7613 (95% CI: 1.5394–2.0152, p < 0.0001; I2 = 81.7%). Notable miRNAs with prognostic significance included miR‐10, miR‐21 and miR‐221. Studies reporting OS HRs less than one had a pooled HR of 0.6805 (95% CI: 0.5862–0.7901, p < 0.0001; I2 = 65.4%). MiRNAs hold promise as diagnostic and prognostic biomarkers for PC. Blood and tissue specimens offer superior diagnostic accuracy, and several miRNAs show potential for predicting patient outcomes.
- Open Access
- 16 January 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (1) , e70346
Comparative Analysis of COVID‐19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center: A Cohort Study
Background and Aims: On March 11, 2020, the World Health Organization declared Coronavirus disease 2019 (COVID‐19) as a pandemic. The spread of the Delta variant of coronavirus started in June 2021 and accounted for the fifth peak of COVID‐19 in Iran in July 2021. According to reports from other countries, vaccination protects against severe diseases caused by COVID‐19, including the Delta variant. Studies have also shown that vaccination provides strong protection against SARS‐CoV‐2 infection, COVID‐19‐related hospitalization, and mortality. This retrospective cohort study was designed based on the medical care monitoring center database of Sayyad Shirazi Hospital. Methods: COVID‐19 confirmed patients' data were extracted for this study from June 22, 2021, to September 22, 2021 including demographic characteristics, signs and symptoms, ICU admission, need for aggressive oxygen therapy, including intubation, mortality, and vaccination status. Results: A total of 2962 patients were enrolled. Being vaccinated was associated with a 4.14‐fold increase in survival (adjusted OR = 4.14; 95% CI: 2.22–7.69; p < 0.01), and individuals in a younger age group demonstrated a 5.58‐fold higher likelihood of surviving (adjusted OR = 5.58; 95% CI: 4.25–8.14; p < 0.01). The risk of severe COVID‐19 was significantly lower in vaccinated individuals, showing a 3.12‐fold decrease in risk (adjusted OR = 3.12; 95% CI: 2.06–4.72; p < 0.01), and in younger age groups, the risk exhibited a 3.28‐fold decrease (adjusted OR = 3.28; 95% CI: 2.66–4.04; p < 0.01). Conclusion: The present results suggest that receiving at least one dose of COVID‐19 vaccine had a significant relationship with decreased COVID‐19 severity and mortality in vaccinated patients compared to unvaccinated patients.
- 16 January 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (1) , e70346
Open AccessComparative Analysis of COVID‐19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center: A Cohort Study
Background and Aims: On March 11, 2020, the World Health Organization declared Coronavirus disease 2019 (COVID‐19) as a pandemic. The spread of the Delta variant of coronavirus started in June 2021 and accounted for the fifth peak of COVID‐19 in Iran in July 2021. According to reports from other countries, vaccination protects against severe diseases caused by COVID‐19, including the Delta variant. Studies have also shown that vaccination provides strong protection against SARS‐CoV‐2 infection, COVID‐19‐related hospitalization, and mortality. This retrospective cohort study was designed based on the medical care monitoring center database of Sayyad Shirazi Hospital. Methods: COVID‐19 confirmed patients' data were extracted for this study from June 22, 2021, to September 22, 2021 including demographic characteristics, signs and symptoms, ICU admission, need for aggressive oxygen therapy, including intubation, mortality, and vaccination status. Results: A total of 2962 patients were enrolled. Being vaccinated was associated with a 4.14‐fold increase in survival (adjusted OR = 4.14; 95% CI: 2.22–7.69; p < 0.01), and individuals in a younger age group demonstrated a 5.58‐fold higher likelihood of surviving (adjusted OR = 5.58; 95% CI: 4.25–8.14; p < 0.01). The risk of severe COVID‐19 was significantly lower in vaccinated individuals, showing a 3.12‐fold decrease in risk (adjusted OR = 3.12; 95% CI: 2.06–4.72; p < 0.01), and in younger age groups, the risk exhibited a 3.28‐fold decrease (adjusted OR = 3.28; 95% CI: 2.66–4.04; p < 0.01). Conclusion: The present results suggest that receiving at least one dose of COVID‐19 vaccine had a significant relationship with decreased COVID‐19 severity and mortality in vaccinated patients compared to unvaccinated patients.
- Open Access
- 9 January 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (1) , e70266
Brain‐Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta‐Analysis
Background: This systematic review and meta‐analysis evaluates peripheral and CNS BDNF levels in glioma patients.Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta‐analysis, and meta‐regression.Results: Eight studies were included. Meta‐analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High‐grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007).Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.
- 9 January 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (1) , e70266
Open AccessBrain‐Derived Neurotrophic Factor (BDNF) as a Potential Biomarker in Brain Glioma: A Systematic Review and Meta‐Analysis
Background: This systematic review and meta‐analysis evaluates peripheral and CNS BDNF levels in glioma patients.Methods: Following PRISMA guidelines, we systematically searched databases for studies measuring BDNF in glioma patients and controls. After screening and data extraction, we conducted quality assessment, meta‐analysis, and meta‐regression.Results: Eight studies were included. Meta‐analysis showed significantly reduced plasma BDNF levels in glioma patients versus controls (SMD: −1.0026; 95% CI: [−1.5284, −0.4769], p = 0.0002). High‐grade gliomas had lower plasma BDNF (p = 0.0288). Tissue BDNF levels were higher in glioma patients (SMD: 1.9513; 95% CI: [0.7365, 3.1661], p = 0.0016) and correlated with tumor grade (p = 0.0122). Plasma BDNF levels negatively correlated with patient age (p = 0.0244) and positively with female percentage (p = 0.0007).Conclusion: BDNF is a promising biomarker in glioma, showing significant changes in plasma and tissue levels correlating with tumor grade, patient age, and gender.
- Open Access
- 18 October 2024
- Published by Wiley
Dubin Johnson Syndrome Presented with Persistence Conjugated Hyperbilirubinemia Unmasked by Brucella Hepatitis: A Case Report
- 18 October 2024
- Published by Wiley
Open AccessDubin Johnson Syndrome Presented with Persistence Conjugated Hyperbilirubinemia Unmasked by Brucella Hepatitis: A Case Report
- Open Access
- 14 June 2024
- Published by MDPI AG in Preprints.org
Epigenetic Alterations of Cognition Functions in Parkinson's Disease
The field of epigenetics, which explores how heritable traits or stable alterations of cell functions occur without changes to the DNA sequence and how environmental factors affect gene expression, is rapidly advancing. Epigenetics plays a critical role in memory formation, learning, and cognitive functioning, effectively bridging genetics with environmental influence. Maternal behavior in rats, for instance, can modify the stress response of their offspring through epigenetic mechanisms such as histone acetylation and DNA methylation. Understanding neurodegenerative diseases like Parkinson's disease (PD) depends on comprehending the mechanisms of epigenetic regulation. Epigenetic modifications, which alter proteins and DNA structure without changing the DNA sequence, can activate or suppress gene expression, assisting organisms in adapting to environmental changes. These modifications may influence genes involved in inflammation, synaptic plasticity, and neuroprotection, potentially contributing to cognitive deficits in PD patients. MicroRNAs (miRNAs), histone modifications, and DNA methylation are the epigenetic mechanisms that significantly influence cell differentiation and maintain normal cellular activity. Understanding the intricate molecular processes of epigenetics could lead to more targeted and effective therapies. Despite numerous findings on how epigenetics affects cognitive alterations in PD patients, only some studies coordinate and integrate these results. Here, we summarize recent findings on how epigenetic changes impact gene expression linked to cognitive impairments in PD.
- 14 June 2024
- Published by MDPI AG in Preprints.org
Open AccessEpigenetic Alterations of Cognition Functions in Parkinson's Disease
The field of epigenetics, which explores how heritable traits or stable alterations of cell functions occur without changes to the DNA sequence and how environmental factors affect gene expression, is rapidly advancing. Epigenetics plays a critical role in memory formation, learning, and cognitive functioning, effectively bridging genetics with environmental influence. Maternal behavior in rats, for instance, can modify the stress response of their offspring through epigenetic mechanisms such as histone acetylation and DNA methylation. Understanding neurodegenerative diseases like Parkinson's disease (PD) depends on comprehending the mechanisms of epigenetic regulation. Epigenetic modifications, which alter proteins and DNA structure without changing the DNA sequence, can activate or suppress gene expression, assisting organisms in adapting to environmental changes. These modifications may influence genes involved in inflammation, synaptic plasticity, and neuroprotection, potentially contributing to cognitive deficits in PD patients. MicroRNAs (miRNAs), histone modifications, and DNA methylation are the epigenetic mechanisms that significantly influence cell differentiation and maintain normal cellular activity. Understanding the intricate molecular processes of epigenetics could lead to more targeted and effective therapies. Despite numerous findings on how epigenetics affects cognitive alterations in PD patients, only some studies coordinate and integrate these results. Here, we summarize recent findings on how epigenetic changes impact gene expression linked to cognitive impairments in PD.
- 30 April 2024
- Published by SeriesScience International in Series of Clinical and Medical Case Reports and Reviews
- Vol. 2 (2) , 1-11
A Systematic Review and Meta-Analysis for Association of Celiac Disease and Thyroid Disorders
- 30 April 2024
- Published by SeriesScience International in Series of Clinical and Medical Case Reports and Reviews
- Vol. 2 (2) , 1-11
A Systematic Review and Meta-Analysis for Association of Celiac Disease and Thyroid Disorders
- Open Access
A Systematic Review and Meta-analysis for Association of Celiac Disease and Thyroid Disorders
It is probable that people who have celiac disease (CD) are more likely to have thyroid disorders. A comprehensive systematic review and meta-analysis were conducted to assess the link between thyroid disorders and CD. Articles were selected from PubMed, Web of Science, Scopus, Ovid, Embase, Cochrane, ProQuest, and Wiley from February 2022 and earlier. A meta-analysis was conducted to evaluate the outcomes, using odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs). The meta-analysis comprised 31 articles with 3310256 participants including 101253 individuals with thyroid disorders. Overall, the frequency of thyroid disease was notably higher in patients with CD compared to the control groups (OR: 3.06, 95% CI: 2.51 – 3.72, P<0.001). The findings of our meta-analysis support the notion that patients with CD are more likely to have autoimmune thyroid disease (ATD) and other thyroid disorders than the control group, thus indicating that regular screening for thyroid disease is necessary for CD patients. Further cohort research is required to investigate the relationship between thyroid disorders and CD.
Open AccessA Systematic Review and Meta-analysis for Association of Celiac Disease and Thyroid Disorders
It is probable that people who have celiac disease (CD) are more likely to have thyroid disorders. A comprehensive systematic review and meta-analysis were conducted to assess the link between thyroid disorders and CD. Articles were selected from PubMed, Web of Science, Scopus, Ovid, Embase, Cochrane, ProQuest, and Wiley from February 2022 and earlier. A meta-analysis was conducted to evaluate the outcomes, using odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs). The meta-analysis comprised 31 articles with 3310256 participants including 101253 individuals with thyroid disorders. Overall, the frequency of thyroid disease was notably higher in patients with CD compared to the control groups (OR: 3.06, 95% CI: 2.51 – 3.72, P<0.001). The findings of our meta-analysis support the notion that patients with CD are more likely to have autoimmune thyroid disease (ATD) and other thyroid disorders than the control group, thus indicating that regular screening for thyroid disease is necessary for CD patients. Further cohort research is required to investigate the relationship between thyroid disorders and CD.